S&P Cuts Outlook for Abbott Labs to Negative

The ratings agency kept the strong credit ratings for the drug maker, but lowered the outlook because of its higher-than-average debt

On June 12, Standard & Poor's lowered its outlook on pharmaceutical manufacturer Abbott Laboratories Inc. to negative from stable, as a result of its higher-than-average debt and expected leverage relative to the rating.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.